Quarterly report · Q2

Period2022-12-01 → 2023-05-31
Filed2023-07-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥26.9bn2022-12-01 → 2023-05-31Cons.Net sales
Revenue¥49.6bn2021-12-01 → 2022-11-30Cons.Net sales (5-year summary)
Revenue¥24.9bn2021-12-01 → 2022-05-31Cons.Net sales
Operating income¥208m2022-12-01 → 2023-05-31Cons.Operating income
Operating income¥720m2021-12-01 → 2022-05-31Cons.Operating income
Ordinary income¥284m2022-12-01 → 2023-05-31Cons.Ordinary income
Ordinary income¥887m2021-12-01 → 2022-11-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥835m2021-12-01 → 2022-05-31Cons.Ordinary income
Profit before tax¥68m2022-12-01 → 2023-05-31Cons.Income before income taxes
Profit before tax¥1.5bn2021-12-01 → 2022-05-31Cons.Income before income taxes
Net income (owners)−¥228m2022-12-01 → 2023-05-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥580m2021-12-01 → 2022-11-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥933m2021-12-01 → 2022-05-31Cons.Profit loss attributable to owners of parent
Net income−¥236m2022-12-01 → 2023-05-31Cons.Profit loss
Net income¥928m2021-12-01 → 2022-05-31Cons.Profit loss
Total assets¥64.8bnat 2023-05-31Cons.Assets
Total assets¥63.6bnat 2022-11-30Cons.Assets
Total assets¥63.9bnat 2022-05-31Cons.Total assets (5-year summary)
Total liabilities¥38.2bnat 2023-05-31Cons.Liabilities
Total liabilities¥36.5bnat 2022-11-30Cons.Liabilities
Net assets / equity¥26.6bnat 2023-05-31Cons.Net assets
Net assets / equity¥27.1bnat 2022-11-30Cons.Net assets
Net assets / equity¥27.8bnat 2022-05-31Cons.Net assets (5-year summary)
Cash and deposits¥5.4bnat 2023-05-31Cons.Cash and deposits
Cash and deposits¥6.9bnat 2022-11-30Cons.Cash and deposits
Cash & equivalents¥5.3bnat 2023-05-31Cons.Cash and cash equivalents
Cash & equivalents¥6.8bnat 2022-11-30Cons.Cash and cash equivalents
Cash & equivalents¥10.3bnat 2022-05-31Cons.Cash and cash equivalents
Cash & equivalents¥10.8bnat 2021-11-30dCons.Cash and cash equivalents
Operating cash flow¥804m2022-12-01 → 2023-05-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥742m2021-12-01 → 2022-11-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.3bn2021-12-01 → 2022-05-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥3.0bn2022-12-01 → 2023-05-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.2bn2021-12-01 → 2022-11-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥23m2021-12-01 → 2022-05-31Cons.Net cash provided by used in investment activities
Financing cash flow¥639m2022-12-01 → 2023-05-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥1.1bn2021-12-01 → 2022-11-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.9bn2021-12-01 → 2022-05-31Cons.Net cash provided by used in financing activities
EPS (basic)¥-5.782022-12-01 → 2023-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-0.552023-03-01 → 2023-05-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥14.562021-12-01 → 2022-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥23.332021-12-01 → 2022-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥12.082022-03-01 → 2022-05-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio40.9%at 2023-05-31Cons.Equity to asset ratio (5-year summary)
Equity ratio42.5%at 2022-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio43.5%at 2022-05-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 61
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-12-01 → 2023-05-31¥4m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-12-01 → 2023-05-31¥4m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-12-01 → 2023-05-31¥669,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-12-01 → 2023-05-31−¥49m
Reconciling Itemsreconcilingrevenue2022-12-01 → 2023-05-31−¥841m
Reconciling Itemsreconcilingrevenue intersegment2022-12-01 → 2023-05-31−¥841m
Reconciling Itemsreconcilingsegment profit2022-12-01 → 2023-05-31¥18m
jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segmentrevenue2022-12-01 → 2023-05-31¥7.8bn
jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segmentrevenue external2022-12-01 → 2023-05-31¥7.3bn
jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segmentrevenue intersegment2022-12-01 → 2023-05-31¥559m
jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segmentsegment profit2022-12-01 → 2023-05-31−¥84m
jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segmentrevenue2022-12-01 → 2023-05-31¥8.9bn
jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segmentrevenue external2022-12-01 → 2023-05-31¥8.8bn
jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segmentrevenue intersegment2022-12-01 → 2023-05-31¥56m
jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segmentsegment profit2022-12-01 → 2023-05-31¥79m
jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segmentrevenue2022-12-01 → 2023-05-31¥4.4bn
jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segmentrevenue external2022-12-01 → 2023-05-31¥4.4bn
jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segmentrevenue intersegment2022-12-01 → 2023-05-31¥35m
jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segmentsegment profit2022-12-01 → 2023-05-31−¥81m
jpcrp040300-q2r_E02585-000Medicalreportable segmentrevenue2022-12-01 → 2023-05-31¥6.6bn
jpcrp040300-q2r_E02585-000Medicalreportable segmentrevenue external2022-12-01 → 2023-05-31¥6.4bn
jpcrp040300-q2r_E02585-000Medicalreportable segmentrevenue intersegment2022-12-01 → 2023-05-31¥191m
jpcrp040300-q2r_E02585-000Medicalreportable segmentsegment profit2022-12-01 → 2023-05-31¥326m
—segment totalrevenue2022-12-01 → 2023-05-31¥27.7bn
—segment totalrevenue external2022-12-01 → 2023-05-31¥26.9bn
—segment totalrevenue intersegment2022-12-01 → 2023-05-31¥840m
—segment totalsegment profit2022-12-01 → 2023-05-31¥239m
Total Of Reportable Segments And Otherssegment totalrevenue2022-12-01 → 2023-05-31¥27.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-12-01 → 2023-05-31¥26.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-12-01 → 2023-05-31¥841m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-12-01 → 2023-05-31¥190m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-12-01 → 2022-05-31¥807,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-12-01 → 2022-05-31¥807,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-12-01 → 2022-05-31−¥19m
Reconciling Itemsreconcilingrevenue2021-12-01 → 2022-05-31−¥740m
Reconciling Itemsreconcilingrevenue intersegment2021-12-01 → 2022-05-31−¥740m
Reconciling Itemsreconcilingsegment profit2021-12-01 → 2022-05-31¥17m
jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segmentrevenue2021-12-01 → 2022-05-31¥7.9bn
jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segmentrevenue external2021-12-01 → 2022-05-31¥7.5bn
jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segmentrevenue intersegment2021-12-01 → 2022-05-31¥348m
jpcrp040300-q2r_E02585-000Fine Chemicalsreportable segmentsegment profit2021-12-01 → 2022-05-31¥474m
jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segmentrevenue2021-12-01 → 2022-05-31¥7.3bn
jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segmentrevenue external2021-12-01 → 2022-05-31¥7.2bn
jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segmentrevenue intersegment2021-12-01 → 2022-05-31¥105m
jpcrp040300-q2r_E02585-000Health And Beauty Care Foodreportable segmentsegment profit2021-12-01 → 2022-05-31−¥66m
jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segmentrevenue2021-12-01 → 2022-05-31¥4.4bn
jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segmentrevenue external2021-12-01 → 2022-05-31¥4.3bn
jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segmentrevenue intersegment2021-12-01 → 2022-05-31¥52m
jpcrp040300-q2r_E02585-000Industrial Chemicalsreportable segmentsegment profit2021-12-01 → 2022-05-31−¥38m
jpcrp040300-q2r_E02585-000Medicalreportable segmentrevenue2021-12-01 → 2022-05-31¥6.1bn
jpcrp040300-q2r_E02585-000Medicalreportable segmentrevenue external2021-12-01 → 2022-05-31¥5.9bn
jpcrp040300-q2r_E02585-000Medicalreportable segmentrevenue intersegment2021-12-01 → 2022-05-31¥235m
jpcrp040300-q2r_E02585-000Medicalreportable segmentsegment profit2021-12-01 → 2022-05-31¥353m
—segment totalrevenue2021-12-01 → 2022-05-31¥25.7bn
—segment totalrevenue external2021-12-01 → 2022-05-31¥24.9bn
—segment totalrevenue intersegment2021-12-01 → 2022-05-31¥740m
—segment totalsegment profit2021-12-01 → 2022-05-31¥722m
Total Of Reportable Segments And Otherssegment totalrevenue2021-12-01 → 2022-05-31¥25.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-12-01 → 2022-05-31¥24.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-12-01 → 2022-05-31¥740m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-12-01 → 2022-05-31¥704m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 636
ItemContextValueUnit
Interest expenses noeCurrentYTDDuration29471000JPY
Equity in losses of affiliates noePrior1YTDDuration7415000JPY
Equity in losses of affiliates noeCurrentYTDDuration11765000JPY
Other noePrior1YTDDuration28217000JPY
Other noeCurrentYTDDuration28223000JPY
Non operating expensesPrior1YTDDuration62563000JPY
Non operating expensesCurrentYTDDuration69460000JPY
Ordinary incomePrior1YTDDuration835016000JPY
Ordinary incomeCurrentYTDDuration283516000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration663894000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration10774000JPY
Gain on donation of a state subsidy eiPrior1YTDDuration24900000JPY
Gain on donation of a state subsidy eiCurrentYTDDuration14827000JPY
Extraordinary incomePrior1YTDDuration688794000JPY
Extraordinary incomeCurrentYTDDuration25601000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration-JPY
Loss on sales of noncurrent assets elCurrentYTDDuration39000JPY
Loss on disposal of noncurrent assets elPrior1YTDDuration5435000JPY
Loss on disposal of noncurrent assets elCurrentYTDDuration20171000JPY
Loss on valuation of investment securities elPrior1YTDDuration-JPY
Loss on valuation of investment securities elCurrentYTDDuration216728000JPY
Loss on transition of retirement benefit plan elPrior1YTDDuration54459000JPY
Loss on transition of retirement benefit plan elCurrentYTDDuration-JPY
Loss on liquidation of subsidiaries and affiliates elPrior1YTDDuration-JPY
Loss on liquidation of subsidiaries and affiliates elCurrentYTDDuration4038000JPY
Extraordinary lossPrior1YTDDuration59895000JPY
Extraordinary lossCurrentYTDDuration240977000JPY
Income before income taxesPrior1YTDDuration1463916000JPY
Income before income taxesCurrentYTDDuration68140000JPY
Income taxes currentPrior1YTDDuration800878000JPY
Income taxes currentCurrentYTDDuration361600000JPY
Income taxes deferredPrior1YTDDuration-264947000JPY
Income taxes deferredCurrentYTDDuration-57804000JPY
Income taxesPrior1YTDDuration535931000JPY
Income taxesCurrentYTDDuration303796000JPY
Profit lossPrior1YTDDuration927985000JPY
Profit lossCurrentYTDDuration-235655000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration-4984000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration-7843000JPY
Profit loss attributable to owners of parentPrior1YTDDuration932969000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-227812000JPY
Profit lossPrior1YTDDuration927985000JPY
Profit lossCurrentYTDDuration-235655000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-79730000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration98348000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration1519000JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration4681000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration76949000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration31360000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-6035000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-11-30pass
balance sheet identityconsolidated 2023-05-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-11-30pass
statement vs summary · net assetsconsolidated 2023-05-31pass
statement vs summary · net income attributable to parentconsolidated 2021-12-01/2022-05-31pass
statement vs summary · net income attributable to parentconsolidated 2022-12-01/2023-05-31pass
statement vs summary · operating cash flowconsolidated 2021-12-01/2022-05-31pass
statement vs summary · operating cash flowconsolidated 2022-12-01/2023-05-31pass
statement vs summary · revenueconsolidated 2021-12-01/2022-05-31pass
statement vs summary · revenueconsolidated 2022-12-01/2023-05-31pass
statement vs summary · total assetsconsolidated 2022-11-30pass
statement vs summary · total assetsconsolidated 2023-05-31pass